Mersana Therapeutics (MRSN) Q2 2024 earnings summary

Executive summary

• Advanced dose escalation in phase I trials for XMT-1660 and XMT-2056, with no maximum tolerated dose reached for XMT-1660 at 80 mg/m², and initial XMT-1660 data expected in H2 2024.

• Earned an $8 million milestone from Johnson & Johnson for Dolasynthen, with payment due in Q3 2024.

• Discontinued UpRi and XMT-1592 programs in 2023 to prioritize next-generation ADCs and collaborations, including a 50% workforce reduction.

• Strategic collaborations with GSK, Johnson & Johnson, and Merck KGaA provide non-dilutive funding and development opportunities.

• Net loss for Q2 2024 was $24.3 million, compared to $54.3 million in Q2 2023.

Financial highlights

• Ended Q2 2024 with $162.7 million in cash, cash equivalents, and marketable securities.

• Collaboration revenue was $2.3 million, down from $10.7 million in Q2 2023, mainly due to lower revenue from Johnson & Johnson and Merck KGaA agreements.

• R&D expenses declined to $17.2 million from $49 million year-over-year, reflecting discontinued programs and restructuring.

• G&A expenses dropped to $10.5 million from $18.2 million year-over-year.

• Net cash used in operating activities for Q2 2024 was $21.8 million, down from $61.8 million year-over-year.

Outlook and guidance

• Initial clinical data readout for XMT-1660, including safety, tolerability, efficacy, and biomarker data, expected in the second half of 2024.

• Expansion cohorts for XMT-1660 are built into the protocol, with flexibility to open one or multiple tumor-specific cohorts based on phase I data.

• Cash runway expected to support operations into 2026, excluding future milestone or collaboration proceeds.

• Plans to initiate expansion portion of XMT-1660 Phase 1 trial and advance XMT-2056 dose escalation in 2024.

• Anticipates continued operating losses for the next several years as clinical and preclinical programs progress.